Medical cannabis for chronic pain: can it make a difference in pain management?

Mari Kannan Maharajan, Yu Jing Yong, Hong Yang Yip, Sze Shee Woon, Kar Mon Yeap, Khai Yeng Yap, Shuen Chi Yip, Kai Xian Yap
Author Information
  1. Mari Kannan Maharajan: Department of Pharmacy Practice, School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia. kanpharm2002@gmail.com. ORCID
  2. Yu Jing Yong: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  3. Hong Yang Yip: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  4. Sze Shee Woon: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  5. Kar Mon Yeap: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  6. Khai Yeng Yap: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  7. Shuen Chi Yip: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  8. Kai Xian Yap: School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.

Abstract

Globally, chronic pain is a major therapeutic challenge and affects more than 15% of the population. As patients with painful terminal diseases may face unbearable pain, there is a need for more potent analgesics. Although opioid-based therapeutic agents received attention to manage severe pain, their adverse drug effects and mortality rate associated with opioids overdose are the major concerns. Evidences from clinical trials showed therapeutic benefits of cannabis, especially delta-9-tetrahydrocannabinol and cannabinoids reduced neuropathic pain intensity in various conditions. Also, there are reports on using combination cannabinoid therapies for chronic pain management. The association of cannabis dependence and addiction has been discussed much and the reports mentioned that it can be comparatively lower than other substances such as nicotine and alcohol. More countries have decided to legalise the medicinal use of cannabis and marijuana. Healthcare professionals should keep themselves updated with the changing state of medical cannabis and its applications. The pharmacokinetics and safety of medical cannabis need to be studied by conducting clinical research. The complex and variable chemically active contents of herbal cannabis and methodological limitations in the administration of cannabis to study participants, make the clinical research difficult.

Keywords

References

  1. J Pain Palliat Care Pharmacother. 2014 Sep;28(3):216-25 [PMID: 25118789]
  2. J Affect Disord. 2015 Jan 15;171:39-47 [PMID: 25285897]
  3. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64 [PMID: 22927402]
  4. Drug Alcohol Depend. 2011 May 1;115(1-2):120-30 [PMID: 21145178]
  5. JAMA. 2015 Jun 23-30;313(24):2474-83 [PMID: 26103031]
  6. J Pain. 2015 Dec;16(12):1233-1242 [PMID: 26385201]
  7. Annu Rev Psychol. 2013;64:21-47 [PMID: 22804774]
  8. Mayo Clin Proc. 2012 Feb;87(2):114-9 [PMID: 22305024]
  9. Compr Psychiatry. 1974 Nov-Dec;15(6):531-5 [PMID: 4426188]
  10. Drug Alcohol Depend. 2017 Aug 1;177:1-13 [PMID: 28549263]
  11. Lancet. 2017 Mar 25;389(10075):1177-1178 [PMID: 28353430]
  12. Int J Drug Policy. 2015 Jan;26(1):15-9 [PMID: 25287942]
  13. J Anesth. 1998 Sep;12(3):142-152 [PMID: 28921182]
  14. J Orthop Surg Res. 2015 Feb 03;10:24 [PMID: 25645576]
  15. Curr Opin Psychiatry. 2007 Jul;20(4):393-7 [PMID: 17551355]
  16. Eur J Intern Med. 2018 Mar;49:12-19 [PMID: 29307505]
  17. Semin Fetal Neonatal Med. 2019 Apr;24(2):149-154 [PMID: 30827870]
  18. J Pain. 2016 Jun;17(6):654-68 [PMID: 26961090]
  19. Subst Abuse. 2015 May 21;9:33-8 [PMID: 26056464]
  20. Accid Anal Prev. 2010 May;42(3):859-66 [PMID: 20380913]
  21. Addiction. 2009 Oct;104(10):1710-7 [PMID: 19663900]
  22. Am J Addict. 2013 Jan;22(1):7-13 [PMID: 23398220]
  23. Br J Clin Pharmacol. 2011 Nov;72(5):735-44 [PMID: 21426373]
  24. Front Pharmacol. 2016 Aug 31;7:285 [PMID: 27630566]
  25. Clujul Med. 2015;88(2):128-36 [PMID: 26528060]
  26. BMJ. 2004 Jul 31;329(7460):253 [PMID: 15258006]
  27. J Addict Med. 2011 Mar;5(1):9-15 [PMID: 21643485]
  28. Cannabis Cannabinoid Res. 2017 May 01;2(1):96-104 [PMID: 28861509]
  29. Biochem Pharmacol. 2018 Nov;157:134-147 [PMID: 30076849]
  30. CNS Neurosci Ther. 2010 Jun;16(3):e72-91 [PMID: 20406253]
  31. Lancet. 2019 Apr 13;393(10180):1537-1546 [PMID: 30983589]
  32. Cannabis Cannabinoid Res. 2018 Sep 01;3(1):179-189 [PMID: 30221197]
  33. Int J Mol Sci. 2018 Mar 13;19(3): [PMID: 29533978]
  34. Exp Clin Psychopharmacol. 2012 Oct;20(5):420-429 [PMID: 22731735]
  35. JAMA Psychiatry. 2016 Mar;73(3):292-7 [PMID: 26842658]
  36. BMJ. 2019 Apr 4;365:l1141 [PMID: 30948383]
  37. J Pain. 2019 Nov;20(11):1362-1372 [PMID: 31132510]
  38. PLoS One. 2017 Nov 16;12(11):e0187795 [PMID: 29145417]
  39. Curr Opin Psychol. 2019 Dec;30:98-102 [PMID: 31071592]
  40. CMAJ. 2008 Jun 17;178(13):1669-78 [PMID: 18559804]
  41. Neuropsychopharmacology. 2009 Feb;34(3):672-80 [PMID: 18688212]
  42. Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634 [PMID: 29017688]
  43. Physiol Rev. 2009 Jan;89(1):309-80 [PMID: 19126760]
  44. Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12624-12626 [PMID: 31182592]
  45. Pain. 2003 Nov;106(1-2):169-72 [PMID: 14581124]
  46. Brain. 2012 Jul;135(Pt 7):2245-55 [PMID: 22669080]
  47. Dig Dis Sci. 2010 Nov;55(11):3113-9 [PMID: 20130993]
  48. Mayo Clin Proc. 2018 Dec;93(12):1842-1847 [PMID: 30522595]
  49. Lancet. 2003 Nov 8;362(9395):1517-26 [PMID: 14615106]
  50. Ann Intern Med. 2017 Sep 5;167(5):319-331 [PMID: 28806817]
  51. Addiction. 2013 Aug;108(8):1459-69 [PMID: 23530710]
  52. J Pain. 2015 Dec;16(12):1221-1232 [PMID: 26362106]
  53. Annu Rev Med. 2016;67:453-66 [PMID: 26515984]
  54. Neuroscience. 2016 Dec 3;338:81-92 [PMID: 27189881]
  55. Eur Addict Res. 2016;22(3):131-44 [PMID: 26551358]
  56. BMC Public Health. 2011 Oct 06;11:770 [PMID: 21978149]
  57. Chem Biodivers. 2007 Aug;4(8):1770-804 [PMID: 17712819]
  58. JAMA Intern Med. 2014 Oct;174(10):1668-73 [PMID: 25154332]
  59. J Biol Chem. 1996 May 31;271(22):13175-83 [PMID: 8662742]
  60. Int J Drug Policy. 2018 Jul;57:4-10 [PMID: 29653439]
  61. J Pain. 2019 Jul;20(7):830-841 [PMID: 30690169]
  62. Exp Clin Psychopharmacol. 2008 Oct;16(5):405-16 [PMID: 18837637]
  63. Pain Physician. 2017 Sep;20(6):E755-E796 [PMID: 28934780]
  64. N Engl J Med. 2014 Jun 5;370(23):2219-27 [PMID: 24897085]
  65. Lancet Public Health. 2018 Jul;3(7):e341-e350 [PMID: 29976328]
  66. Neurology. 2007 Feb 13;68(7):515-21 [PMID: 17296917]
  67. Pain Rep. 2018 Mar 05;3(2):e643 [PMID: 29756089]
  68. Pharmacol Rev. 2002 Jun;54(2):161-202 [PMID: 12037135]
  69. JAMA. 2015 Jun 23-30;313(24):2456-73 [PMID: 26103030]
  70. Am J Addict. 2009 Jul-Aug;18(4):301-8 [PMID: 19444734]
  71. Cannabis Cannabinoid Res. 2017 Jun 01;2(1):160-166 [PMID: 28861516]
  72. Clin Pharmacol Ther. 1975 Jul;18(1):84-9 [PMID: 50159]
  73. Neuropharmacology. 2004;47 Suppl 1:24-32 [PMID: 15464123]
  74. Int J Obes (Lond). 2006 Apr;30 Suppl 1:S13-8 [PMID: 16570099]
  75. Handb Exp Pharmacol. 2005;(168):299-325 [PMID: 16596779]
  76. J Pain. 2016 Jun;17(6):739-44 [PMID: 27001005]
  77. J Pharmacol Exp Ther. 2005 Jul;314(1):329-37 [PMID: 15831444]
  78. Int J Drug Policy. 2017 Apr;42:30-35 [PMID: 28189912]
  79. Pain. 2018 Oct;159(10):1932-1954 [PMID: 29847469]
  80. Health Aff (Millwood). 2019 Feb;38(2):295-302 [PMID: 30715980]
  81. Addict Behav. 2009 Mar;34(3):319-22 [PMID: 19022584]
  82. Drug Alcohol Depend. 1997 Jan 10;44(1):11-29 [PMID: 9031816]
  83. Eur J Intern Med. 2018 Mar;49:7-11 [PMID: 29325791]
  84. PLoS One. 2017 Jul 10;12(7):e0181064 [PMID: 28700706]
  85. Prev Med. 2017 Nov;104:13-23 [PMID: 28705601]
  86. Pain Manag. 2019 Mar 1;9(2):131-138 [PMID: 30806566]
  87. J Pain. 2008 Jun;9(6):506-21 [PMID: 18403272]
  88. J Med Toxicol. 2017 Mar;13(1):71-87 [PMID: 28000146]
  89. Int J Drug Policy. 2015 May;26(5):446-52 [PMID: 25661483]
  90. Minerva Anestesiol. 2018 Aug;84(8):955-969 [PMID: 29338150]
  91. Open Neurol J. 2012;6:18-25 [PMID: 22629287]
  92. J Pain. 2013 Feb;14(2):136-48 [PMID: 23237736]
  93. Continuum (Minneap Minn). 2014 Oct;20(5 Peripheral Nervous System Disorders):1426-9 [PMID: 25299291]
  94. J Stud Alcohol Drugs. 2015 May;76(3):406-13 [PMID: 25978826]
  95. Can Fam Physician. 2018 Feb;64(2):e78-e94 [PMID: 29449262]
  96. Addiction. 2016 Aug;111(8):1348-59 [PMID: 26878835]
  97. Cochrane Database Syst Rev. 2018 Mar 07;3:CD012182 [PMID: 29513392]

MeSH Term

Cannabinoids
Cannabis
Chronic Pain
Humans
Medical Marijuana
Pain Management

Chemicals

Cannabinoids
Medical Marijuana

Word Cloud

Created with Highcharts 10.0.0cannabispainchronictherapeuticclinicalmajorneedreportscanmedicalresearchmakeMedicalGloballychallengeaffects15%populationpatientspainfulterminaldiseasesmayfaceunbearablepotentanalgesicsAlthoughopioid-basedagentsreceivedattentionmanagesevereadversedrugeffectsmortalityrateassociatedopioidsoverdoseconcernsEvidencestrialsshowedbenefitsespeciallydelta-9-tetrahydrocannabinolcannabinoidsreducedneuropathicintensityvariousconditionsAlsousingcombinationcannabinoidtherapiesmanagementassociationdependenceaddictiondiscussedmuchmentionedcomparativelylowersubstancesnicotinealcoholcountriesdecidedlegalisemedicinalusemarijuanaHealthcareprofessionalskeepupdatedchangingstateapplicationspharmacokineticssafetystudiedconductingcomplexvariablechemicallyactivecontentsherbalmethodologicallimitationsadministrationstudyparticipantsdifficultpain:differencemanagement?AddictionChronicDependenceRegulations

Similar Articles

Cited By